RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Michael Gordon of Fenway still part of PMN?BottomBroker wrote: let's refocus our attention to PMN and forget about false investor reports...
That would be ideal but there's no news to focus on.
There is instead an anchor holding us back: the desired benefit-turned-guilt by association with Aduhelm which our CEO has since doubled down on despite the parade of bad news. It does not inspire confidence.
(so azzymaa, this is not about Aduhelm, it's about our CEO and his board support)
Volume has dried up so in a way maybe Gene was right, if in the wrong direction. But if you are potential investor doing DD and you find comments like the one below, are you going to invest with a CEO that touted Aduhelm and now appears to have learned nothing?
Rob Howard, professor of psychiatry at the University College London, wrote on Twitter recently, “Aducanumab has no clinical efficacy and was always going to go down. Biogen always knew this (otherwise would have published the trial outcomes data) and have been allowed to run far too far with a useless agent. They must be more open about lecanemab or we risk another sad saga.”
https://endpts.com/biogen-slams-coverage-proposal-for-amyloid-targeted-alzheimers-drugs-in-31-page-comment/